The partnership between CDMOs and emerging biotech companies in early-stage development can be mutually beneficial. In this interview by PHARMAnetwork magazine, Dr. Raymond Donninger, Senior Director, Commercial Development, Early Development Services, and Dr. James Berrie, Technical Director, Global Process Development explore how the expertise, efficiency, and scalability a CDMO can provide is crucial for efficiently and cost-effectively delivering new therapeutic candidates for an investigational new drug (IND) filing and first-in-human (FIH) trials.
With a focus on collaborative innovation, regulatory compliance, and long-term relationships, this interview provides a comprehensive overview of how partnering with a CDMO can translate into later success for emerging biotechs. It is a must-read for anyone biotechs looking to optimize their early-stage development strategies.